Laboratorios Farmaceuticos Rovi, SA Financials

Market Capitalization €3.24 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	26.91
Forward PE	20.32
Price to Sales TTM	€4.48
Price to Book MRQ	€5.22
Enterprise to Revenue	4.60
Enterprise to EBITDA	19.26

Financial Reports as of Sep. 30, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-09-30
Profit Margin	16.73%
Operating Margin	32.30%
Return on Assets TTM	10.46%
Return on Equity TTM	20.34%

Income Statement

Revenue TTM	€724,200,000
Revenue per Share TTM	€14.16
Quarterly Revenue Growth	-10.50%
Gross Profit TTM	€451,908,000
EBITDA	€288,012,000
Net Income to Common TTM	€121,154,000
Diluted EPS TTM	€2.36
Quarterly Earnings Growth YoY	-16.10%

Balance Sheet

Total Cash MRQ	€49,250,000
Total Cash per Share MRQ	€0.96
Total Debt MRQ	€
Total Debt to Equity MRQ	19.54
Current Ratio MRQ	3.02
Book Value per Share MRQ	€12.16

Cash Flow

Operating Cash Flow TTM	€174,519,008
Levered Free Cash Flow TTM	€53,108,000

ROVI Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	51,149,498
Float Shares	16,654,277
Avg 10 Volume	94,587
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	67.33%
% Held by Institutions	18.95%

Stock Price Summary

Beta	0.15
Fifty Two Week Low	€45.52
Fifty Two Week High	€66.55
Fifty Two Week Change	0.55%
Day 50 MA	€60.43
Day 200 MA	€56.23

Dividends and Splits

Forward Annual Dividend Rate	€3.74
Forward Annual Dividend Yield	5.90%
Trailing Annual Dividend Rate	€0.94
Trailing Annual Dividend Yield	1.48%
Payout Ratio	39.58%
Dividend Date
Ex Dividend Date	2025-07-14
Last Split Factor
Last Split Date